FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Avoiding FDA Warning Letters: Why High Level Biodecontamination Is Essential in Pharma Manufacturing On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver